Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
101
resultados
Última actualización
14/09/2026 [07:09:00]
Resultados 50 a 75 de 101
Resumen de: US20260232759A1
Anti-SARS-CoV-2 α/β-polypeptides, pharmaceutical compositions containing the same, and methods to inhibit, treat, and ameliorate SARS-CoV-2 infections in mammals, including humans.
Resumen de: US20260234220A1
0000 The present invention provides neutralizing monoclonal antibodies targeting the spike protein of Sarbecoviruses, such as Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-1 or SARS-CoV-2 like COVID-19). The monoclonal antibodies of the invention can inhibit or neutralize SARS-CoV-1 or SARS-CoV-2 activity and advantageously be used for treating, preventing or diagnosing COVID-19 infection in humans due to their significant cross-reactivity among SARS-CoV-2 variants.
Resumen de: US20260234629A1
0000 The present invention relates to a new antisense oligonucleotide, a pharmaceutical composition comprising it and their use for preventing or treating infection by coronavirus, especially by SARS-CoV-2 virus which causes the infection disease COVID-19.
Resumen de: US20260234221A1
The disclosure relates to a pharmaceutical composition comprising human plasma-derived polyclonal, anti-SARS-CoV-2 hyperimmune globulins and to said pharmaceutical composition for use in the treatment of a SARS-CoV-2 Omicron variant infection. The disclosure also relates to a method for the preparation of a polyclonal, hyperimmune globulin composition anti-SARS-CoV-2.
Resumen de: US20260234196A1
Disclosed in the present invention are a polypeptide and a polypeptide composition specifically binding to a SARS-CoV-2 spike protein, and preparation methods and the uses thereof. By means of binding to S1 protein, the polypeptide and the polypeptide composition can block the binding of SARS-CoV-2 virus to a key target protein angiotensin-converting enzyme 2 (ACE2) protein on the surface of a host cell thereof, thereby providing a feasible targeting drug for the treatment of Coronavirus disease 2019.
Resumen de: US20260235601A1
0000 The present invention relates to development of novel ssDNA aptamers comprising the oligonucleotide sequence that detect receptor-binding domain (RBD) of Severe Acute Respiratory Syndrome Corona virus (SARS-nCOV-2) infection. The ssDNA aptamers of the present invention may be used in lateral flow assays, electrochemical sensors and calorimetric sensors using gold nanoparticles. The present invention also relates to an analytical composition comprising said ssDNA aptamers. Further, the present invention also relates to a diagnostic kit for detecting RBD of SARS-nCoV-2.
Resumen de: WO2025073771A1
The present invention inter alia relates to an use of an isolated polypeptide or an antigenic fragment thereof, comprising a polypeptide region having at least 60% sequence identity with any one of the polypeptide sequences selected from the group consisting of SEQ ID No.: 1-11, 16-20 and 23-28; wherein the isolated polypeptide is having a length of no more than 200 contiguous amino acids for diagnosing Long COVID or Post-Vac-Syndrome, or for predicting a risk of developing Long COVID or Post-Vac-Syndrome. The present invention also relates to the isolated polypeptide or antigenic fragment thereof for use in preventing, treating or ameliorating Long COVID or Post-Vac-Syndrome., as well as to a method of detecting a presence of antibodies against SARS-CoV-2 in a subject, comprising the step of contacting a sample of said subject with at least one of the polypeptide or antigenic fragment thereof.
Resumen de: EP4790065A1
Coronavirus spike protein variants for use in antigens for vaccines for coronavirus infection are provided.A coronavirus spike protein variant comprising:(a) a receptor binding domain (RBD) consisting of an amino acid sequence set forth in SEQ ID NO: 1;(b) an RBD consisting of an amino acid sequence obtained by substituting, deleting, inserting, or adding one to several amino acids in the amino acid sequence set forth in SEQ ID NO: 1, and having neutralizing antibody-inducing activity against SARS-CoV-2 and SARS-CoV-1 equivalent to that of an RBD consisting of the amino acid sequence set forth in SEQ ID NO: 1; or(c) an RBD consisting of an amino acid sequence that has at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO: 1, and having neutralizing antibody-inducing activity against SARS-CoV-2 and SARS-CoV-1 equivalent to that of the RBD consisting of the amino acid sequence set forth in SEQ ID NO: 1.
Resumen de: US20260227402A1
0000 Disclosed is a high-performance anti-SARS-CoV-2 antibody and a detection reagent using it. The method of detecting SARS-CoV-2 includes detecting SARS-CoV-2 in a sample by an immunoassay method using a monoclonal antibody that specifically reacts with the RNA-binding domain in the N protein of SARS-CoV-2, or an antigen-binding fragment thereof. The detection kit for SARS-CoV-2 includes a monoclonal antibody that specifically reacts with the RNA-binding domain in the N protein of SARS-CoV-2, or an antigen-binding fragment thereof.
Resumen de: US20260227400A1
0000 Disclosed is a high performance anti-SARS-CoV-2 antibody and a detection reagent using it. The method of detecting SARS-CoV-2 includes detecting SARS-CoV-2 in a sample by an immunoassay method using a monoclonal antibody that specifically reacts with 301aa-319aa, 301aa-320aa, or 351aa-375aa of the amino acid sequence of the N protein of SARS-CoV-2, or an antigen-binding fragment thereof. The detection kit for SARS-CoV-2 includes a monoclonal antibody that specifically reacts with 301aa-319aa, 301aa-320aa, or 351aa-375aa of the amino acid sequence of the N protein of SARS-CoV-2, or an antigen-binding fragment thereof.
Resumen de: US20260227401A1
Disclosed is a high performance anti-SARS-CoV-2 antibody and a detection reagent using it. The method of detecting SARS-CoV-2 includes detecting SARS-CoV-2 in a sample by an immunoassay method using a monoclonal antibody that specifically reacts with the N protein of SARS-CoV-2, or an antigen-binding fragment thereof. The detection kit for SARS-CoV-2 includes a monoclonal antibody that specifically reacts with the N protein of SARS-CoV-2, or an antigen-binding fragment thereof.
Resumen de: US20260226140A1
Disclosed are a monoclonal antibody capable of rapidly, simply, and highly sensitively detecting and measuring SARS-CoV-2 contained in a test sample, and an immunoassay method and immunoassay device for SARS-CoV-2 using the same. The monoclonal antibody or its antigen-binding fragment includes heavy chain CDR1-CDR3 having specific amino acid sequences and light chain CDR1-CDR3 having specific amino acid sequences. The immunoassay method for SARS-CoV-2 includes performing an immunoassay of SARS-CoV-2 utilizing an antigen-antibody reaction between this monoclonal antibody or its antigen-binding fragment and SARS-CoV-2 in a sample.
Resumen de: US20260226425A1
An isolated nucleic acid comprising a recombinant coronavirus genome having a genetic modification that provides cold-adapted growth relative to a parent virus that is not cold-adapted and a vaccine comprising the recombinant genome and methods of using the vaccine are provided.
Resumen de: WO2026165023A1
The present disclosure is directed to antibodies binding to and neutralizing Middle East Respiratory Syndrome-Related Coronavirus (MERS-CoV) and methods for use thereof.
Resumen de: AU2026206109A1
Provided are methods for treating 2019-nCoV virus (SARS-CoV-2) infections by administering nucleosides and prodrugs thereof, of Formula I: , wherein the 1’ position of the nucleoside sugar is substituted. R¹ R¹¹¹ R¹ R³ X"" R² ul u l ¹ ²
Resumen de: WO2026163139A1
The present disclosure relates to the use of β-lactoglobulin in the treatment of a viral condition, wherein β-lactoglobulin is in its native protein state, wherein the viral condition is caused by a human Rotavirus strain or Coronavirus OC43. The present disclosure further relates to a pharmaceutical composition comprising β-lactoglobulin and one or more pharmaceutically acceptable excipients, wherein the pharmaceutical composition further comprises at least one additional therapeutic agent.
Resumen de: AU2025219283A1
The present disclosure relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.
Resumen de: AU2025218930A1
The present disclosure relates to compounds of Formula I and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.
Resumen de: WO2026163027A1
Provided herein is a replication-defective coronavirus having in its genome a modification, wherein the modification results in a reduced expression of the M gene compared to a coronavirus lacking the modification.
Resumen de: US20260226034A1
0000 Methods and compositions for treating SARS-CoV-2 and COVID-19 are disclosed. Sulfone-1H-pyrrole-2-carboxamides of the following formula
0000
0000 inhibit the SARS-CoV-2 PLpro/NSP3 protein and are therefore useful for treating SARS-CoV-2 and COVID-19.
Resumen de: CN122029189A
The present invention provides antibodies that bind to the SARS-CoV-2 spike (S) protein. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions and methods of using the above antibodies that bind to the SARS-CoV-2 spike (S) protein.
Resumen de: US20260216194A1
Disclosed herein are methods of treating a taste and smell disorder caused by a viral infection in a subject, comprising administering to the subject a phosphodiesterase inhibitor. Also disclosed herein are methods of treating taste and smell loss from COVID-19 by administering a phosphodiesterase inhibitor to a subject in need thereof.
Resumen de: US20260217840A1
The present invention relates to an antibody specifically binding to an IL-10 receptor and use thereof. The antibody targets IL-10 signaling and has an excellent effect of suppressing cytokine storm and excessive inflammation in severe inflammatory infectious diseases, and in particular, can be effectively used in suppressing inflammatory responses in severe SARS-CoV-2 infection and fatal SFTSV infection.
Resumen de: AU2026205425A1
Abstract Provided is a composition comprising a phenyl pyrrole aminoguanidine derivative for use in a method of treating viral disorders and diseases, including symptomatic viral disorders and diseases, including symptomatic COVID-19. 5 Abstract ul b s t r a c t u l
Nº publicación: US20260217797A1 30/07/2026
Solicitante:
TAKEDA PHARMACEUTICAL CO LIMITED [JP]
Takeda Pharmaceutical Company Limited
Resumen de: US20260217797A1
Disclosed herein are antibodies that bind to coronavirus spike protein (e.g., SARS-CoV-2 spike protein), and methods of use thereof (e.g., treatment of subjects infected with SARSCoV-2).
BOPI
Sede Electrónica
